Regulatory & market landscape
Amycretin arrived amid intense interest in a multi-billion-dollar obesity market, and its novel design drew attention f…
A drug the market is watching, not yet selling
Amycretin arrived amid intense interest in a multi-billion-dollar obesity market, and its novel design drew attention fast. Yet as of 2026 it is approved nowhere, its phase 3 program is enrolling rather than reporting, and a "research peptide" shadow market has already formed around an unavailable, unverified drug.
This unit maps the regulatory reality, the transition from dose-finding to confirmatory trials, the athlete and legal considerations, and the honest bottom-line verdict on a promising but still-unproven molecule.
Key terms
The regulatory status
The headline is simple: amycretin is approved nowhere as of 2026. No FDA, EMA, or Japanese (PMDA) approval exists, and there is no Orange Book listing. Following the June 2025 readouts, Novo Nordisk announced both formulations would advance to phase 3, and the AMAZE program opened its first trial in February 2026. That is the start of the approval journey, not the end: a trial that is enrolling has proved nothing.
The anti-doping row below is read straight off WADA's own 2026 documents rather than off commentary. The 2026 Monitoring Program lists markers of semaglutide and tirzepatide, in- and out-of-competition, and the 2026 Prohibited List names no GLP-1, incretin, or amylin receptor agonist in any category. Amycretin appears on neither.
The regulatory picture is coherent: a novel drug with striking early data but no confirmatory evidence yet, now running the large trials approval requires. The dependence on a full phase 3 program is important; early-phase readouts, however eye-catching, do not make a filing.
AdvancedWhy phase 3 will take years
Phase 3 obesity trials typically enroll thousands of participants over a year or more, plus follow-up, analysis, and regulatory review. Amycretin also has two formulations, each needing its own program, and its flagship obesity trial (AMAZE 1) reads out its primary endpoint at week 84 with a primary completion date in 2029. Even on an aggressive timeline, that puts any possible approval years away, and every step could reshape the picture, including the possibility that the striking small-arm numbers do not hold up at scale.